SUXAMETHONIUM (A)

(Revised: January 2014)

	T	
ТҮРЕ:	Depolarising muscle relaxant [S4]	
	_	
PRESENTATION:	100mg in 2ml – plastic ampoule	
ACTION:	Acts like the neurotransmitter acetylcholine at the neuromuscular junction. Persists for a period long enough to exhaust the motor endplate by prolonged depolarisation.	
	Onset IV: approx 45 seconds. Duration IV: 5 – 7 minutes.	
USE:	ICP	To facilitate airway management in selected patients
ADVERSE EFFECTS:	1. Bradycardia	
	2. Po	tassium release
	3. Inc	creased intraocular and intragastric pressure
	4. Oc	casionally, prolonged paralysis
	5. Has been associated with malignant hyperthermia	
CONTRA-	1. Previous reaction to suxamethonium	
INDICATIONS:	2. Suspected hyperkalaemia	
		e in children
PRECAUTIONS:	1. Elc	derly patient
	2. Ne	euromuscular disease
	3. Hy	pothermic patient
	4. Fit	ting patient
	5. Pa	tient with reversible pathology
	Selec	t patients carefully – always have a fallback position!

continues over

SUXAMETHONIUM (A) – cont.



DOSE:

ADULT:			
ICP	1.5mg/kg IV – over 30 – 60 seconds (to a maximum of 150mg)		
PAEDIATRIC:			
	Not used		

SPECIAL NOTES:

- To be used *only* following completion of the ACTAS designated training programme.
- If heart rate less than 50/minute, consider atropine prior to suxamethonium.
- Suxamethonium may cause bradycardia. If patient is bradycardic once ETT is tied in, consider a dose of atropine.
- (NOTE: Bradycardia may be a result of a head injury and raised ICP thus, BP will be elevated. In this case there is no requirement for atropine regardless of the degree of bradycardia).
- Prior to administration, give IV ketamine 1mg/kg, over 30 60 seconds.
- Follow up with additional ketamine (1mg/kg doses IV at 1 5 minute intervals) after intubation.